2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
117
Triple Negative Breast Neoplasms
27
Neoplasm Metastasis
18
Sarcoma
17
Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Brain Neoplasms
5
Prostatic Neoplasms
4
Urinary Bladder Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Liposarcoma
3
Inflammatory Breast Neoplasms
3
HER2-negative Breast Cancer
3
Carcinoma, Transitional Cell
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Leiomyosarcoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Advanced Breast Cancer
2
Interventions
Fulvestrant
18
Letrozole
10
Anastrozole
8
Capecitabine
5
palbociclib
4
olaparib
4
Paclitaxel
4
Goserelin
4
Docetaxel
4
pyrotinib
3
exemestane
3
Vinorelbine
3
Injections
3
Aromatase Inhibitors
3
trastuzumab deruxtecan
2
toripalimab
2
sacituzumab govitecan
2
ribociclib
2
eribulin
2
elacestrant
2
dalpiciclib
2
abemaciclib
2
Trastuzumab
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Everolimus
2
Dasatinib
2
Alpelisib
2
Albumin-Bound Paclitaxel
2
AZD9833
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
eribulin
×
Clear all
NCT05530057
2025-11-20
ESPERO
Seoul National University Hospital
Phase 2
Recruiting
180 enrolled
NCT04826016
2023-03-20
POLTER
MedSIR
Phase 1/2
Withdrawn